| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445375 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
The 25Â mg/m2 dose of cabazitaxel was recommended for use in future clinical studies. In this study, cabazitaxel had an acceptable tolerability profile and activity in cervical, colorectal, endometrial and lung cancers.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
V. Diéras, A. Lortholary, V. Laurence, R. Delva, V. Girre, A. Livartowski, S. Assadourian, D. Semiond, J.Y. Pierga,